Local NewsBusiness ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing By Digital AIM Web Support - February 8, 2021 FacebookTwitterPinterestWhatsApp Like this:Like Loading... Related Featured Local Savings Featured Local Savings